HUTCHMED Reports Strong First-Half Earnings and Maintains Full-Year Guidance
HUTCHMED reported first-half oncology revenue of $162 million in H1 2026, a 23% increase year-over-year. The company remained profitable with net income of $16 million and ended the period with $1.4 billion in cash reserves. Strong performance was driven by China sales growth for ELUNATE and SULANDA, both up over 40%, as well as international expansion of FRUZAQLA, which saw a 70% increase outside the U.S. The company maintained its full-year oncology revenue guidance between $330 million to $415 million. Pipeline advancements included positive Phase III results for sovleplenib in warm autoimmune hemolytic anemia and upcoming data readouts for savolitinib, along with a new trial launch for HMPL-760 in diffuse large B-cell lymphoma. HUTCHMED is also exploring collaborations on its ATTC programs. R&D expenses increased to $79 million due to global trials of ATTC assets and investments in AI capabilities.
Tickers: $HCM
Topics: financial performance oncology drugs pharmaceuticals